Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Accenture
Fish and Richardson
Novartis
Fuji
Queensland Health
Argus Health
US Department of Justice
Harvard Business School
Medtronic

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022202

« Back to Dashboard

NDA 022202 describes ZIPSOR, which is a drug marketed by Depomed Inc and is included in one NDA. It is available from one supplier. There are eight patents protecting this drug and one Paragraph IV challenge. Additional details are available on the ZIPSOR profile page.

The generic ingredient in ZIPSOR is diclofenac potassium. There are forty-seven drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the diclofenac potassium profile page.
Summary for 022202
Tradename:ZIPSOR
Applicant:Depomed Inc
Ingredient:diclofenac potassium
Patents:8
Therapeutic Class:Analgesics
Anti-inflammatory Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 022202
Suppliers and Packaging for NDA: 022202
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ZIPSOR diclofenac potassium CAPSULE;ORAL 022202 NDA Depomed, Inc. 13913-008 13913-008-12 120 CAPSULE, LIQUID FILLED in 1 BOTTLE (13913-008-12)
ZIPSOR diclofenac potassium CAPSULE;ORAL 022202 NDA Depomed, Inc. 13913-008 13913-008-11 100 CAPSULE, LIQUID FILLED in 1 BOTTLE (13913-008-11)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength25MG
Approval Date:Jun 16, 2009TE:ABRLD:Yes
Patent:➤ SubscribePatent Expiration:Jan 15, 2019Product Flag?YSubstance Flag?Delist Request?
Patent:➤ SubscribePatent Expiration:Jul 15, 2019Product Flag?YSubstance Flag?Delist Request?
Patented Use:NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
Patent:➤ SubscribePatent Expiration:Feb 24, 2029Product Flag?Substance Flag?Delist Request?
Patented Use:NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Johnson and Johnson
Baxter
Chubb
US Department of Justice
Chinese Patent Office
AstraZeneca
Express Scripts
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot